Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Hector Cordero-Nieves, BS, Douglas W. Sborov, MD, Alessandro Canella, MS, Zhongfa Liu, Jessica Consiglio, MS, Wenjun Ni, Emily Smith, Lara Rizzotto, PhD, Yvonne A Efebera, MD, Don M. Benson, MD PhD, Luciano Cascione, Mo Xiaokui, MS, John C. Byrd, MD, Michael R. Grever, MD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2014) 124 (21): 3377.

https://doi.org/10.1182/blood.V124.21.3377.3377

Published: 2014

Journal Articles

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Craig C. Hofmeister, MD, Zhongfa Liu, Ph.D., Mindy A Bowers, BS, Pierluigi Porcu, MD, Joseph M. Flynn, DO, MPH, Beth Christian, MD, Robert A. Baiocchi, M.D., Ph.D., Don M. Benson, Jr., MD, PhD, Leslie A Andritsos, MD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Susan Geyer, PhD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2012) 120 (21): 2955.

https://doi.org/10.1182/blood.V120.21.2955.2955

Published: 2012

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Blood (2009) 113 (25): 6411–6418.

https://doi.org/10.1182/blood-2008-07-170589

Published: 2009

Includes: Supplemental data

Journal Articles

TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia

Blood (2009) 113 (22): 5558–5567.

https://doi.org/10.1182/blood-2009-02-205732

Published: 2009

Includes: Supplemental data

Journal Articles

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Kristie A. Blum, MD, Zhongfa Liu, David M. Lucas, Robert Baiocchi, Thomas S. Lin, Don Benson, Steven M. Devine, Jeffrey Jones, Leslie Andritsos, Joseph Flynn, Ping Cheng, Zhiliang Xie, Guido Marcucci, Kenneth K. Chan, Michael R. Grever, John C. Byrd

Blood (2008) 112 (11): 3169.

https://doi.org/10.1182/blood.V112.11.3169.3169

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2008) 112 (11): 2957.

https://doi.org/10.1182/blood.V112.11.2957.2957

Published: 2008

Journal Articles

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

Blood (2008) 111 (4): 2364–2373.

https://doi.org/10.1182/blood-2007-08-110171

Published: 2008

Journal Articles

MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML).

Ramiro Garzon, Shujun Liu, Muller Fabbri, Zhongfa Liu, Jiuxia Pang, Natarajan Muthusamy, William Blum, Kenneth Chan, John C. Byrd, Carlo M. Croce, Guido Marcucci

Blood (2007) 110 (11): 718.

https://doi.org/10.1182/blood.V110.11.718.718

Published: 2007

Journal Articles

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

Shujun Liu, PhD, Jiuxia Pang, Jianhua Yu, Ph.D., Zhongfa Liu, Ph.D., Lenguyen Huynh, Jessica Kearney, Peter Paschka, M.D., Rebecca B. Klisovic, M.D., Robert Baiocchi, M.D., William Blum, M.D., Danilo Perrotti, Ph.D., Guido Marcucci, M.D.

Blood (2006) 108 (11): 4211.

https://doi.org/10.1182/blood.V108.11.4211.4211

Published: 2006

Journal Articles

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

Amy J. Johnson, PhD, Ryan Edwards, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Carlo M. Croce, MD, Natarajan Muthusamy, DVM, PhD, Ching-Shih Chen, PhD, Zhongfa Liu, PhD, Kenneth Chan, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2005) 106 (11): 51.

https://doi.org/10.1182/blood.V106.11.51.51

Published: 2005

Journal Articles

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

William Blum, MD, Rebecca Bruner-Klisovic, MD, Shujun Liu, PhD, John C. Byrd, MD, Zhongfa Liu, PhD, Kenneth K. Chan, PhD, Cheryl Kefauver, R.N., Lenguyen Huynh, Michael R. Grever, MD, Guido Marcucci, MD

Blood (2005) 106 (11): 1861.

https://doi.org/10.1182/blood.V106.11.1861.1861

Published: 2005

NARROW

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML).

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only